Journal Article (Review Article) DKFZ-2025-00341

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Onconephrology: The Significance of Renal Function for the Development, Diagnosis, and Treatment of Cancer.

 ;  ;  ;  ;

2024
Dt. Ärzte-Verl. Köln

Deutsches Ärzteblatt international 121(24), 793-799 () [10.3238/arztebl.m2024.0193]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: Modern treatment strategies have markedly improved the chances of survival for patients with cancer. As the population ages, cancer is becoming more common, as is chronic kidney disease (CKD). CKD increases the risk of cancer; conversely, cancer treatments can cause CKD.This review is based on publications retrieved by a selective literature search concerning the epidemiology and comorbidities of cancer and kidney diseases, the renal side effects of new anticancer drugs, and the need to consider renal function in cancer treatment.The prevalence of severe CKD in Germany is 2.3%. Persons who have CKD, are on dialysis, or have undergone kidney transplantation are 1.2 to 3.5 times more likely to develop cancer than the general population. For patients who have CKD or are dialysis-dependent, the doses of approximately 67% of anticancer drugs need to be adjusted on the basis of their glomerular filtration rate and the renally excreted fraction of the drug. The optimal efficacy of therapeutic drugs, as well as of those used for diagnostic purposes, and the minimization of side effects, depend critically on adapted dosing and on proper timing of administration before or after dialysis. Modern anticancer drugs can also cause acute kidney damage (incidence with checkpoint inhibitors: 2-16%).Patients who have CKD, are on dialysis, or have undergone kidney transplantation make up a considerable fraction of persons being treated for cancer, and they need interdisciplinary treatment.

Keyword(s): Humans (MeSH) ; Neoplasms: complications (MeSH) ; Neoplasms: therapy (MeSH) ; Renal Insufficiency, Chronic: therapy (MeSH) ; Renal Insufficiency, Chronic: complications (MeSH) ; Renal Insufficiency, Chronic: diagnosis (MeSH) ; Renal Insufficiency, Chronic: physiopathology (MeSH) ; Antineoplastic Agents: adverse effects (MeSH) ; Germany: epidemiology (MeSH) ; Glomerular Filtration Rate (MeSH) ; Kidney Transplantation (MeSH) ; Renal Dialysis (MeSH) ; Prevalence (MeSH) ; Antineoplastic Agents

Classification:

Note: #EA:D400# / https://di.aerzteblatt.de/int/archive/article/241946

Contributing Institute(s):
  1. Pathologie infektionsbedingter Tumoren (D400)
Research Program(s):
  1. 314 - Immunologie und Krebs (POF4-314) (POF4-314)

Appears in the scientific report 2024
Database coverage:
Medline ; Clarivate Analytics Master Journal List ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2025-02-13, last modified 2025-02-16



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)